益美國際(01870.HK)授出儲能產品獨家經銷權 拓馬來西亞及柬埔寨新能源業務
益美國際(01870.HK)公布,其附屬信能中和已各自與一間於馬來西亞註冊成立的公司及一間於柬埔寨註冊成立的公司訂立獨家經銷協議,公司將在馬來西亞及柬埔寨等地區發展其新能源業務。
根據獨家經銷協議,信能中和(作為便攜式儲能產品供應商,涉足於有關系統的開發、設計、生產及銷售)將向獨家經銷商供應以其自有品牌「SUNEWTRAL」為主的高質素儲能產品及提供相關服務,以於馬來西亞及柬埔寨推廣「SUNEWTRAL」儲能產品及發展新能源業務。東南亞其他區域的代理銷售管道也正加緊建設中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.